RFRyuji Fukushima

Ryuji Fukushima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryuji Fukushima has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Aritada Yoshimura

    Animal Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan

    14 shared publications
  • Daiki Hirao

    Koganei Animal Emergency Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan

    11 shared publications
  • Takahiro Ohmori

    Koganei Animal Emergency Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan

    9 shared publications
  • Shohei Morita

    Koganei Animal Emergency Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan

    8 shared publications
  • Shusaku Yamada

    Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan

    6 shared publications
  • Takae Kawaguchi

    Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan

    6 shared publications

Latest Publications

  • Open Access

    37,X/38,XY mosaicism in a cat with a female phenotype and an enlarged clitoris

    by Aritada Yoshimura, Takahiro Kondo, Shohei Morita, Daiki Hirao, Kazuhiko Suzuki, Ryuji Fukushima

    A 10-month-old mixed-breed cat was presenting a female appearance; however, a detailed examination of external genitalia revealed an enlarged clitoris with spines. The urethra opened into the vagina. Laparotomy and subsequent histopathological examination revealed that both ovaries were replaced by hypoplastic testes, with underdeveloped uteruses located caudal to them. Chromosome and genetic testing using peripheral blood revealed that the cat displayed a nearly 1:1 mosaicism of the 37,X and 38,XY chromosomes and presence of the SRY gene. Only two cases of 37,X/38,XY mosaicism have been reported in cats, both displaying a normal penis and prepuce, indicating a male phenotype. To the best of our knowledge, this is the first report of 37,X and 38,XY mosaicism manifesting as a female phenotype.


  • Open Access

    Systemic gene expression mapping of voltage-gated calcium channel α1-subunits in cats

    by Takumi Matsuura, Shohei Morita, Ryuji Fukushima

    Background: In veterinary medicine, voltage-gated calcium channels (VGCCs) are key drug targets. Calcium channel blockers (CCBs) are the standard treatment for common feline diseases, such as systemic hypertension and hypertrophic cardiomyopathy. However, therapeutic strategies are limited due to the adverse effects of existing drugs like amlodipine, such as activation of the renin-angiotensin-aldosterone system. A critical lack of feline-specific data on the tissue distribution of VGCC subtypes fundamentally hinders the safe and effective application of CCBs in cats. This is because knowledge from other species is often not translatable due to the unique metabolic pathways in cats. Aim: To fill this critical data gap, the present study created the first baseline quantitative map of the mRNA expression of seven major VGCC α1-subunits across a comprehensive range of feline tissues. Methods: Twelve tissue types were collected from a single 16-month-old male cat. Using a validated TaqMan probe-based quantitative real-time PCR assay, we measured the relative mRNA expression of seven CaV α1-subunit genes: CACNA1S (CaV1.1), CACNA1C (CaV1.2), CACNA1D (CaV1.3), CACNA1F (CaV1.4), CACNA1B (CaV2.2), CACNA1G (CaV3.1), and CACNA1H (CaV3.2). Relative transcript abundance was calculated using the 2-ΔCt method with 18S rRNA as the endogenous control for normalization. Results: The seven VGCC genes exhibited distinct, tissue-specific expression patterns. CACNA1S expression was predominantly localized to skeletal muscle. The heart showed the highest expression of CACNA1C and CACNA1H. The brain displayed prominent CACNA1B, CACNA1C, and CACNA1G expression. The mesenteric lymph node also showed significant CACNA1C, CACNA1F, and CACNA1G expression. Conversely, the liver and pancreas consistently displayed very low expression for most of the channel genes investigated. Conclusion: This study provides the first foundational mRNA expression map of major VGCC α1-subunits in feline tissues. The results reveal unique expression profiles that highlight both conserved physiological functions and significant differences compared to other species, particularly in cardiac and lymphoid tissues. These molecular data are vital for advancing feline pharmacology by enabling more accurate predictions of the therapeutic and adverse effects of CCBs and provide a critical resource for future investigations into feline channelopathies.

  • Open Access

    Effect of pimobendan on myocardial injury and systolic dysfunction in a canine model of supraventricular tachyarrhythmia

    by Daiki Hirao, Shohei Morita, Hiroshi Hasegewa, Aritada Yoshimura, Takae Kawaguchi, Shusaku Yamada, Takahiro Oomori, Kazuhiko Suzuki, Ryuji Fukushima

    Supraventricular tachyarrhythmia (SVTA) in dogs can cause cardiac dysfunction and may progress to heart failure. Pimobendan, an inotropic agent with calcium-sensitizing and phosphodiesterase III inhibition, is widely used in veterinary medicine. However, its influence on myocardial injury under persistent SVTA remains incompletely understood. This study aimed to evaluate whether pimobendan improves systolic function without exacerbating myocardial injury, using a canine model of rapid atrial pacing (RAP). Fourteen healthy Beagle dogs were allocated to either a control or pimobendan group. RAP was performed for three weeks at 390 bpm. Cardiac function was assessed by echocardiography before (baseline) and after RAP (3W). Concurrently, cardiac troponin I (cTnI) concentrations were measured to assess myocardial injury. In the control group, a significant increase in cTnI was observed at 3W compared with baseline (0.023 ± 0.029 ng/mL vs. 0.176 ± 0.173 ng/mL). Additionally, in the control group, echocardiographic parameters worsened, including fractional shortening (FS) (37.8 ± 4.6% vs. 24.5 ± 6.8%) and stroke volume (SV) (15.8 ± 3.1 mL vs. 10.5 ± 2.0 mL) at 3W compared with baseline. In contrast, the pimobendan group showed no significant differences in these echocardiographic parameters. cTnI concentrations also remained within the normal range without significant differences. These results suggest that pimobendan preserved systolic function without aggravating myocardial injury during sustained SVTA. Pimobendan may therefore be safe and effective cardiac inotropic agent for the treatment of dogs with SVTA.

  • Open Access

    Long-term management of paroxysmal atrioventricular block with Wenckebach cycles in a dog

    by Shohei Morita, Shiho Taguchi, Takahiro Kondo, Aritada Yoshimura, Shiori Ikoma, Takahiro Ohmori, Daiki Hirao, Noboru Machida, Hisashi Hirose, Ryuji Fukushima

    This is the first report of paroxysmal atrioventricular block with Wenckebach cycles in a dog exhibiting syncope. The patient was a 1-year-old female Shiba Inu referred to our hospital with chief complaints of exercise intolerance, dizziness during walking, and tongue discoloration. Pacemaker implantation was performed based on the clinical presentation and Holter electrocardiogram findings. In this case, long-term management was successfully achieved for 13 years and 3 months (Age 15 years old) after the placement of pacemaker. A histopathological examination revealed that no abnormalities in the conduction system were detected that could explain the arrhythmia. Consequently, the arrhythmia was suspected to have been caused by vagus nerve stimulation.


  • Open Access

    Effects of Beraprost with or without NOS Inhibition on Plasma Aldosterone and Hemodynamics in Healthy Cats

    by Takumi Matsuura, Aritada Yoshimura, Ryuji Fukushima

    Objectives: The aim of the study was to evaluate the hemodynamic and RA system effects of the oral administration of the clinical dose of beraprost for feline CKD in healthy cats, and also to examine whether NOS inhibition reversed them. Methods: A placebo-controlled pharmacological sequential design study was carried out to assess the plasma aldosterone and renin concentrations (PAC and PRC), blood pressure, heart rate, and exploratorily to estimate renal plasma flow (RPF) and renal vascular resistance (RVR) with simplified methods. Results: Beraprost reduced PAC when compared to the placebo (p < 0.05); this was reversed when NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was added to the beraprost treatment (p < 0.01). No differences in the PRC or hemodynamic parameters were detected between beraprost and the placebo. The correlation ratios (η2) showed opposite relationships between beraprost and the added L-NAME effects on PAC, mean blood pressure (MBP), heart rate, estimated RPF (p < 0.001), estimated RVR (p < 0.01), and PRC (p < 0.05). Conclusions: In healthy cats, the clinical dose of beraprost suppresses PAC, which can be reversed by the inhibition of NOS.


  • Open Access

    Situational syncope caused by vomiting in a cat

    by Daiki Hirao, Ryohei Kato, Keisuke Sakaguchi, Takahiro Ohmori, Shohei Morita, Hiroshi Hasegawa, Aritada Yoshimura, Ryuji Fukushima

    A 14-year-old spayed female mixed-breed cat weighing 3.4 kg was admitted to the Tokyo University of Agriculture and Technology Animal Medical Center for syncope after vomiting. Echocardiography, electrocardiography, and thoracic radiography revealed no abnormalities. Holter electrocardiography showed a paroxysmal high-grade atrioventricular block coinciding with the vomiting. Based on these findings, the cat was diagnosed as having situational syncope with paroxysmal high-grade atrioventricular block triggered by vomiting, which improved with antiemetic treatment alone. The cat subsequently died of chronic kidney disease approximately 3 years and 4 months after the initial diagnosis. This is the first reported case of situational syncope triggered by vomiting in a cat.

  • Open Access

    Use of amlodipine in the treatment of cats with systemic hypertension in Japan

    by Shohei Morita, Youhei Mochizuki, Itsuki Matsumoto, Ayumi Horii, Takahiro Ohmori, Daiki Hirao, Hiroshi Hasegawa, Aritada Yoshimura, Takashi Baba, Shuji Suzuki, et al.

    An increase in systemic blood pressure causes bleeding and ischemia owing to peripheral vascular breakdown, leading to various forms of organ damage. The brain, eyes, kidneys, and cardiovascular system are known target organs for hypertension. To our knowledge, no reports in Japan describe, in detail, the types of antihypertensive drugs used to treat hypertension in cats or its underlying causes. Therefore, we aimed to investigate the use of antihypertensive drugs in domestic cats with hypertension in Japan, the causes of hypertension, and the vital prognosis of these patients. In the present survey, we found that amlodipine was used alone (60/80 cats) or concomitantly (20/80 cats) in all cat patients with hypertension in Japan. We also determined that blood pressure measurements were not yet routinely performed on cats at veterinary clinics in Japan. Furthermore, we have new information suggesting that amlodipine administration in cats with hypertension, which lowers systolic arterial pressure levels to within the normal range (<140 mmHg), may have a negative impact on their survival. Routine blood pressure measurements for cats during their regular health checkups can help identify hypertension, and proper interpretation of blood pressure readings can facilitate suitable treatment measures.


  • Open Access

    Effects of Beraprost with or without NOS Inhibitor on Aldosterone and Hemodynamics in Healthy Cats

    by Takumi Matsuura, Aritada Yoshimura, Ryuji Fukushima

    Objectives: The aim of the study was to evaluate the effects of oral administration of clinical dose of beraprost for feline CKD in healthy cats, and also to examine whether NOS inhibition reversed them. Methods: A placebo-controlled pharmacological sequential design study was carried out to assess plasma aldosterone and renin concentrations, mean blood pressure, heart rate, renal plasma flow, and renal vascular resistance. Results: Beraprost reduced plasma aldosterone when compared to the placebo (P < 0.05); this was reversed when NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was added to beraprost treatment (P < 0.01). No differences in the plasma renin concentration or hemodynamic parameters were detected between beraprost and placebo. The correlation ratios (η2) showed opposite relationships between beraprost and added L-NAME effects on aldosterone concentration, mean blood pressure, heart rate, renal plasma flow, and renal vascular resistance (P < 0.001). Conclusions: In healthy cats, the clinical dose of beraprost suppresses plasma concentration of aldosterone, which can be reversed by inhibition of NOS.

  • Open Access

    A case of a dog with paragonimiasis after consumption of raw deer meat

    by Aritada Yoshimura, Daigo Azakami, Miori Kishimoto, Takahiro Ohmori, Daiki Hirao, Shohei Morita, Shinogu Hasegawa, Tatsushi Morita, Ryuji Fukushima

    A 6-year-old castrated male Cavalier King Charles Spaniel was referred to the Animal Medical Center, Tokyo University of Agriculture and Technology, for examination and treatment of recurrent pneumothorax. Chest radiography and computed tomography showed multiple cavitary lesions in the caudal right posterior lobe. These lesions were surgically excised via thoracotomy. Subsequent histopathological examination revealed paragonimiasis. In the postoperative review, we found that the owner had fed raw deer meat to the dog four months earlier. Deer meat has attracted attention as a source of Paragonimus in humans. To our knowledge, this is the first report of Paragonimus infection in a dog due to deer meat consumption.


  • Open Access

    Efficacy of cilostazol in canine bradyarrhythmia

    by Takahiro Ohmori, Yuri Matsumura, Aritada Yoshimura, Shohei Morita, Hiroshi Hasegawa, Daiki Hirao, Ryuji Fukushima

    Recently, cilostazol, a phosphodiesterase III inhibitor, has been described as alternative medical treatment for canine bradyarrhythmia in cases for which pacemaker implantation was not indicated or available. In this retrospective study, we investigated the use and efficacy of cilostazol in dogs with bradyarrhythmia in Japan. Dogs that had been brought to the Tokyo University of Agriculture and Technology Animal Medical Center and 23 veterinary hospitals in Japan and been treated with cilostazol initially as the only therapeutic strategy for bradyarrhythmia between January 2010 and August 2021 were included in this study. Survival analyses were performed using Cox proportional hazards analysis, the log-rank test, and the generalized Wilcoxon test to evaluate the efficacy of cilostazol. Fifty-nine privately owned dogs were included in this study. In the survival time analysis, the risk of death was significantly lower and the survival rate was higher in cases in which cilostazol was administered at 10 mg/kg or more per dose. A third-degree atrioventricular block also significantly increased the risk of death and was associated with a lower survival rate. However, in some patients with a third-degree atrioventricular block, there was an increase in the ventricular rate and improvement in clinical symptoms without disappearance or decrease of the atrioventricular block. This study had several important findings that have not previously been reported concerning the use of cilostazol for canine bradyarrhythmia, including the appropriate dose in a clinical setting and the efficacy and prognosis according to the type of bradyarrhythmia.